Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases

Abstract

Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.

Data Sources Data were collected from PubMed/MedLine, ClinicalTrials.gov; the years 2007 to 2018 were searched for English-language articles. Search terms: “bromocriptine and peripartum cardiomyopathy”, “bromocriptine and cardiomyopathy.”

Methods of Study Selection This search strategy yielded 171 articles. After excluding duplicates, 86 studies were reviewed. Sixty-one articles involving the treatment of PPCMP were included, and of these, 17 were case reports of patients with PPCMP treated with bromocriptine; these studies were included in this review.

Tabulation, Integration, and Results Seventeen of these articles were case reports of patients with peripartum cardiomyopathy treated with bromocriptine that were included.

Conclusion Bromocriptine seems to be a promising treatment, there is currently insufficient evidence for universal utilization of bromocriptine for all patients with PPCMP. Addition of bromocriptine to the standard heart failure therapy should be individualized.

Keywords

peripartum cardiomyopthaty - bromocriptine - left ventricular function - recovery - pregnancy - right ventricular function

Précis

Bromocriptine seems to be a promising treatment for peripartum cardiomyopathy but there is a need for further clinical trials.

• References

• 1 Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016; 133 (14) 1397-1409
• 2 Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 1971; 44 (05) 964-968
• 3 Demakis JG, Rahimtoola SH, Sutton GC. , et al. Natural course of peripartum cardiomyopathy. Circulation 1971; 44 (06) 1053-1061
• 4 Sliwa K, Hilfiker-Kleiner D, Petrie MC. , et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12 (08) 767-778
• 5 Kolte D, Khera S, Aronow WS. , et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 2014; 3 (03) e001056
• 6 Brar SS, Khan SS, Sandhu GK. , et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100 (02) 302-304
• 7 Bouabdallaoui N, Mouquet F, Lebreton G, Demondion P, Le Jemtel TH, Ennezat PV. Current knowledge and recent development on management of peripartum cardiomyopathy. Eur Heart J Acute Cardiovasc Care 2017; 6 (04) 359-366
• 8 Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 2014; 11 (06) 364-370
• 9 Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25 (03) 118-123
• 10 Yancy CW, Jessup M, Bozkurt B. , et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013; 62 (16) e147-e239
• 11 Yancy CW, Jessup M, Bozkurt B. , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 68 (13) 1476-1488
• 12 Bollen IA, Van Deel ED, Kuster DW, Van Der Velden J. Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart. Front Physiol 2015; 5: 531
• 13 Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152 (03) 509-513
• 14 Fett JD, Sannon H, Thélisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet 2009; 104 (02) 125-127
• 15 Elkayam U, Tummala PP, Rao K. , et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344 (21) 1567-1571
• 16 Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368 (9536): 687-693
• 17 Sliwa K, Förster O, Libhaber E. , et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27 (04) 441-446
• 18 Hilfiker-Kleiner D, Kaminski K, Podewski E. , et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128 (03) 589-600
• 19 Forster O, Hilfiker-Kleiner D, Ansari AA. , et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008; 10 (09) 861-868
• 20 Rayburn WF. Clinical commentary: the bromocriptine (Parlodel) controversy and recommendations for lactation suppression. Am J Perinatol 1996; 13 (02) 69-71
• 21 Bernard N, Jantzem H, Becker M. , et al; French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey. BJOG 2015; 122 (09) 1244-1251
• 22 Sliwa K, Blauwet L, Tibazarwa K. , et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121 (13) 1465-1473
• 23 Hilfiker-Kleiner D, Haghikia A, Berliner D. , et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017; 38 (35) 2671-2679
• 24 Haghikia A, Schwab J, Vogel-Claussen J. , et al. Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clin Res Cardiol 2018
• 25 Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 2017; 38 (35) 2680-2682
• 26 Hilfiker-Kleiner D, Meyer GP, Schieffer E. , et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007; 50 (24) 2354-2355
• 27 Habedank D, Kühnle Y, Elgeti T, Dudenhausen JW, Haverkamp W, Dietz R. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 2008; 10 (11) 1149-1151
• 28 Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol 2008; 199 (04) e5-e6
• 29 Abe T, Amano I, Sawa R, Akira S, Nakai A, Takeshita T. Recovery from peripartum cardiomyopathy in a Japanese woman after administration of bromocriptine as a new treatment option. J Nippon Med Sch 2010; 77 (04) 226-230
• 30 Meyer GP, Labidi S, Podewski E, Sliwa K, Drexler H, Hilfiker-Kleiner D. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J Med Case Reports 2010; 4: 80
• 31 Emmert MY, Prêtre R, Ruschitzka F, Krähenmann F, Falk V, Wilhelm MJ. Peripartum cardiomyopathy with cardiogenic shock: recovery after prolactin inhibition and mechanical support. Ann Thorac Surg 2011; 91 (01) 274-276
• 32 Ballo P, Betti I, Mangialavori G, Chiodi L, Rapisardi G, Zuppiroli A. Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine. Case Rep Med 2012; 2012: 476903
• 33 Freerksen N, Jaekel J, Menon AK, Maass N, Bauerschlag D. Massive respiratory dysfunction as sign of fulminant peripartum cardiomyopathy (PPCM). Hypertens Pregnancy 2012; 31 (04) 451-453
• 34 Hilfiker-Kleiner D, Struman I, Hoch M, Podewski E, Sliwa K. 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heart Fail Rep 2012; 9 (03) 174-182
• 35 Schroeter MR, Unsöld B, Holke K, Schillinger W. Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump. Clin Res Cardiol 2013; 102 (02) 155-157
• 36 Kotlica BK, Cetković A, Plesinac S, Macut D, Asanin M. Peripartum cardiomyopathy: a case of patient with triplet pregnancy. Clin Exp Obstet Gynecol 2016; 43 (02) 274-275
• 37 Hamdan R, Nassar P, Zein A, Issa M, Mansour H, Saab M. Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcome after left ventricular assistance. J Crit Care 2017; 37: 185-188
• 38 Horn P, Saeed D, Akhyari P, Hilfiker-Kleiner D, Kelm M, Westenfeld R. Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy. ESC Heart Fail 2017; 4 (04) 641-644
• 39 Senanayake HM, Patabendige M. Two potentially lethal conditions of probable immune origin occurring in a pregnant woman: a case report. J Med Case Reports 2018; 12 (01) 158
• 40 Kryczka KE, Dzielińska Z, Franaszczyk M. , et al. Severe course of peripartum cardiomyopathy and subsequent recovery in a patient with a novel TTN gene-truncating mutation. Am J Case Rep 2018; 19: 820-824
• 41 Huang Y, Chen T, Zhang M, Yang X, Ding G, Yang L. Successful management of fatal peripartum cardiomyopathy in a young pregnant woman: a case report. Medicine (Baltimore) 2018; 97 (15) e0408